xRead - Globus and Chronic Cough (April 2024)

Wamkpah et al.

Page 22

Author Manuscript Author Manuscript Author Manuscript Author Manuscript # Patients enrolled; completed therapy (males/ females) Average age in years Comparator Treatment duration Primary outcome measure

Secondary outcome measure(s)

Placebo oral tablets (30) 12 weeks LCQ Cough frequency (cough/hr)

Cough symptom score Urge-to-cough score

Laryngeal dysfunction score

24-hr cough frequency (coughs/hr) HRCQ

Cough severity VAS

Urge-to-cough VAS CQLQ

Cough symptom diary

24-hr and nighttime cough frequency (coughs/hr) CQLQ

Cough severity VAS

Urge-to-cough VAS

Cough global rating of change

Capsaicin and ATP cough challenge

Urge-to-cough VAS

8 weeks LCQ Cough severity score FeNO

Cough severity VAS

Urge-to-cough VAS LCQ Capsaicin cough challenge

Cough global rating of change

Placebo oral tablet daily (15) 8 weeks Modified RSI VHI-10 Overall symptom severity

Perceived degree (%) of symptom change

cough

challenge

4 weeks Capsaicin cough

challenge

2 weeks Daytime cough frequency

(coughs/hr)

frequency

(coughs/hr)

2 weeks Daytime cough frequency

(coughs/hr)

Placebo oral tablet Single dose Capsaicin

Placebo oral tablet Single dose Daytime cough Placebo oral tablet

intervention (n patients)

domperidone 10 mg TID (120)

Placebo oral tablet daily

Placebo oral tablet BID

daily for 3 days, then

TID for remainder of

treatment period (21)

Placebo oral tablet BID

63.1 TRPV-1 inhibitor: XEN

52 Capsaicin capsule 0.4 mg BID × 2 weeks, then 0.8 mg BID × 2 weeks 54.5 P2X3 inhibitor: AF-219 600 mg BID

NCT02397460 (2015) UK Crossover RCT 24; 24 (sex NR) NR P2X3 inhibitor: AF-219 50

Neuromodulator:

53 TRPV-1 inhibitor: SB-705498

Macrolide antibiotic: azithromycin 500 mg daily for 3 days, then 250

Tricyclic antidepressant: amitriptyline 12.5 mg

Experimental

intervention (n patients)

Gabapentin titrated up

to 1800 mg daily, then tapered off (32)

mg (12 patients), AF-219 300 mg (12 patients)

mg TID for remainder of treatment period (21) D0501 4 mg BID

qHS, maximum 50 mg daily (15)

E: 62.7

C: 60.9

E: 59.6

C: 56.9

E: 42

C: 49

(22/40)

21; 19

(6/15)

24; 22

(2/22)

24; 18

(6/18)

(14/30)

20; 18

(5/15)

(11/7)

number (year) Location Study design

Parallel RCT 62; 52

Crossover RCT

Crossover RCT

Crossover RCT

Parallel RCT 44; 20 Crossover RCT

Parallel RCT 30; 19

Newcastle, NSW,

Australia

Manchester,

England, UK

Gothenburg, Sweden

Manchester,

England, UK

Nottingham,

England, UK

London,

England, UK

Boston, MA, USA

Ryan et al (2012)

Khalid et al (2014)

Ternesten

Abdulqawi et al (2015)

Hodgson et al (2016)

Belvisi et al (2017)

Jang et al (2017)

Author or

clinical trial

Hasseus et al (2014)

Laryngoscope . Author manuscript; available in PMC 2022 January 01.